Skip to main content

and
  1. Article

    Open Access

    Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma

    Lung cancer is the leading cause of cancer death, partially owing to its extensive heterogeneity. The analysis of intertumor heterogeneity has been limited by an inability to concurrently obtain tissue from sy...

    Runzhe Chen, Jun Li, Junya Fujimoto in Journal of Experimental & Clinical Cancer … (2022)

  2. Article

    Open Access

    Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma

    The original version of this article unfortunately contained a mistake.

    Pedro Rocha, Ruth Salazar, Jiexin Zhang, Debora Ledesma in Cancer Immunology, Immunotherapy (2021)

  3. Article

    Open Access

    CD8+ T cells inhibit metastasis and CXCL4 regulates its function

    The mechanism by which immune cells regulate metastasis is unclear. Understanding the role of immune cells in metastasis will guide the development of treatments improving patient survival.

    Robiya Joseph, Rama Soundararajan, Suhas Vasaikar, Fei Yang in British Journal of Cancer (2021)

  4. Article

    Open Access

    CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma

    CD73 is a membrane-bound enzyme crucial in adenosine generation. The adenosinergic pathway plays a critical role in immunosuppression and in anti-tumor effects of immune checkpoint inhibitors (ICI). Here, we i...

    Pedro Rocha, Ruth Salazar, Jiexin Zhang, Debora Ledesma in Cancer Immunology, Immunotherapy (2021)

  5. Article

    Open Access

    A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

    EGFR tyrosine kinase inhibitors (TKIs) induce cytolysis and release of tumour proteins, which can stimulate antigen-specific T cells. The safety and efficacy of durvalumab and gefitinib in combination for TKI-...

    Benjamin C. Creelan, Tammie C. Yeh, Sang-We Kim in British Journal of Cancer (2021)

  6. No Access

    Article

    MBIP (MAP3K12 binding inhibitory protein) drives NSCLC metastasis by JNK-dependent activation of MMPs

    Metastasis is the cause for 90% of cancer-related mortalities. Identification of genetic drivers promoting dissemination of tumor cells may provide opportunities for novel therapeutic strategies. We previously...

    Joshua Kapere Ochieng, Samrat T. Kundu, Rakhee Bajaj, B. Leticia Rodriguez in Oncogene (2020)

  7. No Access

    Article

    IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgi-mediated secretion

    Non-small cell lung cancer (NSCLC) is the deadliest form of cancer worldwide, due in part to its proclivity to metastasize. Identifying novel drivers of invasion and metastasis holds therapeutic potential for ...

    Rakhee Bajaj, Samrat T. Kundu, Caitlin L. Grzeskowiak, Jared J. Fradette in Oncogene (2020)

  8. No Access

    Article

    18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer

    Enhanced tumor glycolytic activity is a mechanism by which tumors induce an immunosuppressive environment to resist adoptive T cell therapy; therefore, methods of assessing intratumoral glycolytic activity are...

    Kyle G. Mitchell, Behrang Amini, Yunfei Wang in Cancer Immunology, Immunotherapy (2020)

  9. Article

    Open Access

    Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches

    The clinical efficacy observed with inhibitors of programed cell death 1/programed cell death ligand 1 (PD-L1/PD-1) in cancer therapy has prompted studies to characterize the immune response in several tumor t...

    Edwin R. Parra, Pamela Villalobos, Carmen Behrens in Journal for ImmunoTherapy of Cancer (2018)